glp 1 eye disease GLP-1/GIP Receptor Agonists and Diabetic Retinopathy: What ODs Should Know GLP-1 Medications and Your Vision:

Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrm LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, De Valk HW, Lis ACS, Parrot-Roulaud FM, Tan KS, Higgins I, and Garcon D (1997)

Lin F et al

inject slowly and steadily [6]

Beyond Novo and Eli Lilly, companies such as Boehringer Ingelhium, Pfizer, Roche, AstraZeneca, Regor therapeutics, Viking Therapeutics, Amgen, BioAge Labs, Gan & Lee Pharmaceuticals, Sun Pharma, Innovent Biologics, Aphaia Pharma, Vertex Pharmaceuticals , and others are entering the space, fueling new innovations in GLP-1 therapies, combination therapies, and next-gen metabolic treatments